Skip to NavigationSkip to content

GSK and Innoviva's triple asthma therapy Trelegy Ellipta impresses at Phase 3

Published on 03/05/19 at 11:01am

GSK and partner Innoviva have lifted the curtain on new Phase 3 data for their single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) in the treatment of uncontrolled asthma, showing that it met its primary endpoint.

The therapy was shown to demonstrate a “statistically significant” improvement in lung function by 110ml, compared to Relvar/Breo Ellipta (FF/VI), as well as a 92ml improvement in trough FEV.

Additionally, Trelegy Ellipta showed a 13% reduction in annualised rate of moderate or severe exacerbations, but this was not deemed statistically significant. The safety profile of the therapy was found to be consistent with previous data.

“We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available,” remarked Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, while Dr Paul Meunier, Vice President of Respiratory Medicine at Innoviva, added: “The CAPTAIN study has shown that triple therapy in a single inhaler provides a potential new treatment option for asthma management in patients uncontrolled on ICS/LABA.” 

 Full details from the study are due to be presented at upcoming scientific meetings and peer-reviewed journals, the companies said.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches